Peptide stapling was first introduced by Verdine and co‐workers in 200022 who then went on to employ the concept to identify peptide‐based inhibitors of Bcl‐2 proteins designed on the structure of the BH3 domain of the BID protein (Table 1, Figure 1), so called “stabilised α‐helix of BCL‐2 domains” (SAHBs).20 BID SAHBA was able to specifically activate the apoptosis pathway in leukaemia cells and inhibit the growth of leukaemia xenografts in vivo. The gene discussed is BCL2; the disease is leukemia.